Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Edward A. Stadtmauer, MD

Edward A. Stadtmauer, MD Physician

Section Chief, Hematologic Malignancies Roseman, Tarte, Harrow, and Shaffer Families' President's Distinguished Professor

Dr. Stadtmauer is employed by Penn Medicine.

About Dr. Edward A. Stadtmauer

Recognized by America's Top Doctors, 2007, 2008, 2010, 2011 - 2018

Recognized by Best Doctors in America 2003 - 2018

Recognized in Philadelphia magazine's annual Top Docs issues from 2005 - 2008, 2011, and 2013 - 2018

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties


  • Hematology
  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 1988
  • Internal Medicine, 1986
  • Medical Oncology, 1989

Clinical Expertise:

  • Autologous Stem Cell Transplantation
  • Blood Cancer
  • Bone Marrow Transplant
  • Multiple Myeloma
  • Stem Cell Transplant

Description of Clinical Expertise

Myeloma, Leukemia, Lymphoma and Bone Marrow and Stem Cell Transplant

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Bronx Municipal Hospital - Albert Einstein College
Fellowship: Hospital of the University of Pennsylvania


American College of Physicians, Fellow, National American Federation for Clinical Research, National American Society for Blood and Marrow Transplantation, National American Society of Clinical Oncology, National American Society of Hematology, National Autologous Bone Marrow Transplant Registry (ABMTR/CIBMTR), National Bone Marrow Transplant Clinical Trials Network, National Eastern Cooperative Oncology Group, National Foundation for the Accreditation of Hematopoietic Cell Therapy, National International Myeloma Working Group, International Membership in External Advisory Committees, Endpoint Review Committees, and Data Safety and Monitoring Boards, International Membership in National Scientific Review Panels, National NCI Myeloma Steering Committee, National NIAID Hematopoietic Stem Cell Transplantation Data Safety Monitoring Board (HSCT DSMB), National

Hospital Affiliation

Dr. Stadtmauer is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Description of Research Expertise:

Clinical trials, Bone Marrow Transplant

Selected Publications:

D'Souza Anita, Pasquini Marcelo, Logan Brent, Giralt Sergio, Krishnan Amrita, Antin Joseph, Howard Alan, Goodman Stacy, Qazilbash Muzzafar, Knust Kristin, Sahebi Firoozeh, Weisdorf Daniel, Vesole David, Stadtmauer Edward, Maloney David, Hari Parameswaran: Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. British journal of haematology 178 (5): 816-819,2017.

Bair Steven M, Strelec Lauren, Nagle Sarah J, Nasta Sunita D, Landsburg Daniel J, Mato Anthony R, Loren Alison W, Schuster Stephen J, Stadtmauer Edward A, Svoboda Jakub: Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. American journal of hematology 92 (9): 879-884,2017.

Holstein Sarah A, Jung Sin-Ho, Richardson Paul G, Hofmeister Craig C, Hurd David D, Hassoun Hani, Giralt Sergio, Stadtmauer Edward A, Weisdorf Daniel J, Vij Ravi, Moreb Jan S, Callander Natalie S, van Besien Koen, Gentile Teresa G, Isola Luis, Maziarz Richard T, Bashey Asad, Landau Heather, Martin Thomas, Qazilbash Muzaffar H, Rodriguez Cesar, McClune Brian, Schlossman Robert L, Smith Scott E, Hars Vera, Owzar Kouros, Jiang Chen, Boyd Molly, Schultz Chelsea, Wilson Marcia, Hari Parameswaran, Shea Thomas C: Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. The Lancet. Haematology 4 (9): e431-e442,2017.

Scott Emma C, Maziarz Richard T, Spurgeon Stephen E, Medvedova Eva, Gajewski James, Reasor-Heard Shara, Park Byung, Kratz Anne, Thomas George V, Loriaux Marc, Cascio Michael, Podolak Jennifer, Gordon Miranda, Botelho Jennifer, Stadtmauer Edward, Amaravadi Ravi, Vogl Dan T: Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma. Haematologica 102 (7): e261-e265,2017.

Cheng Yee Chung, Shi Yushu, Zhang Mei-Jie, Brazauskas Ruta, Hemmer Michael T, Bishop Michael R, Nieto Yago, Stadtmauer Edward, Ayash Lois, Gale Robert Peter, Lazarus Hillard, Holmberg Leona, Lill Michael, Olsson Richard F, Wirk Baldeep Mona, Arora Mukta, Hari Parameswaran, Ueno Naoto: Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. Journal of Cancer 8 (6): 1009-1017,2017.

Narayan Vivek, Gunnarsson Orvar, Hwang Wei-Ting, Squillante Christian M, Nathanson Katherine L, Stadtmauer Edward A, Vaughn David J: Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors. Clinical genitourinary cancer 14 (6): 524-529,2016.

Yam Clinton, Crisalli Lisa, Luger Selina M, Loren Alison W, Hexner Elizabeth O, Frey Noelle V, Mangan James K, Gao Amy, Stadtmauer Edward A, Porter David L, Reshef Ran: Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. American journal of hematology 91 (9): 883-7,2016.

Yam Clinton, Landsburg Daniel J, Nead Kevin T, Lin Xinyi, Mato Anthony R, Svoboda Jakub, Loren Alison W, Frey Noelle V, Stadtmauer Edward A, Porter David L, Schuster Stephen J, Nasta Sunita D: Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. American journal of hematology 91 (7): 672-6,2016.

Jacobus S J, Rajkumar S V, Weiss M, Stewart A K, Stadtmauer E A, Callander N S, Dreosti L M, Lacy M Q, Fonseca R: Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood cancer journal 6 (7): e448,2016.

Kumar Anita J, Vassilev Pavel, Loren Alison W, Luger Selina M, Reshef Ran, Gill Saar, Smith Jacqueline, Goldstein Steven C, Hexner Elizabeth, Stadtmauer Edward A, Porter David, Frey Noelle V: Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI. American journal of hematology 91 (4): 426-9,2016.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-171
3400 Civic Center Blvd

Philadelphia, PA 19104
Phone: (215) 662-7910
Patient appointments: 800-789-7366 (PENN)

Related Links